title: Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
abstract: To investigate the changes in bone metabolism markers after second-line treatment with loading dose intravenous (i.v.) ibandronate in patients with bone metastases (BM) from breast cancer, 80 patients were enrolled in this study during January 2010 to April 2014. All the patients were treated with a second-line loading dose ibandronate for advanced breast cancer with BM and moderate-to-severe bone pain. Ibandronate (6 mg) was intravenously administered on three consecutive days followed by maintenance treatment every 3-4 weeks. Clinical data, including pain score, Karnofsky performance status (KPS) score, and changes in bone metabolism markers, were analyzed. Sixty-two patients were included in the final analysis. Compared with their pre-treatment scores, patients exhibited significantly increased KPS scores (P < .01) and a reduced dose of analgesic medication (oxycodone) (P < .01) after 3 and 6 weeks' post-treatment. The levels of serum bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase (TRACP-5b), and cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) were significantly reduced after 3 and 6 weeks' post-treatment (P < .001). Aside from a few adverse events, no liver or renal toxicity was observed. Bone metabolism markers decreased by varying degrees after treatment with a loading dose of ibandronate in patients with BM from breast cancer. It might be convenient using bone metabolism markers to potentially evaluate the efficacy of bisphosphonates treatment for bone metastasis.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of PLA General Hospital, Beijing, China.
authors.forename: Ruliang
authors.initials: R
authors.lastname: Wang
authors.affiliation: Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
authors.forename: Shaohua
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
authors.forename: Zefei
authors.initials: Z
authors.lastname: Jiang
authors.affiliation: Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
authors.forename: Jizheng
authors.initials: J
authors.lastname: Tian
authors.affiliation: Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
authors.forename: Santai
authors.initials: S
authors.lastname: Song
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001859:Bone Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007262:Infusions, Intravenous; D008875:Middle Aged; D010455:Peptides / Q000097:blood; D012189:Retrospective Studies; D000071681:Tartrate-Resistant Acid Phosphatase / Q000097:blood; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; C000605510:ACP5 protein, human; D000071681:Tartrate-Resistant Acid Phosphatase; D000077557:Ibandronic Acid
keywords: advanced breast cancer; bone metabolism markers; bone metastases (BM); ibandronate; loading dose